CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Crinetics Pharmaceuticals, Inc.

Building No. 2
10222 Barnes Canyon Road
San Diego, CA 92121
United States
858 450 6464

Full Time Employees68

Key Executives

NameTitlePayExercisedYear Born
Dr. R. Scott StruthersFounder, Pres, CEO & Director715.39kN/A1962
Mr. Marc J. C. WilsonCFO & Sec.450kN/A1979
Dr. Alan S. KrasnerChief Medical Officer571.97kN/A1963
Dr. Yun-Fei ZhuFounder & VP of ChemistryN/AN/A1963
Dr. Stephen F. BetzCo-Founder & VP of BiologyN/AN/A1966
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Corporate Governance

Crinetics Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.